ClinicalTrials.gg
Status unknownNCT02530398Updated Aug 30, 2017

A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites

A Phase 1 interventional study of Cinobufacini Injection in Digestive System Cancer and Malignant Ascites, sponsored by Dongfang Hospital Beijing University of Chinese Medicine. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-30.

Sponsored by Dongfang Hospital Beijing University of Chinese Medicine · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Digestive System Neoplasms with a site in China — 35 open to participants now, 40 under way, 4 of them phase 3. Digestive System Neoplasms · China.

Planned enrollment
36th of 64
48 · median 60
Started
2015
with 2 others
Phase 1
18 of 75
13 open now
Registered
9th of 75
by date

Among the 75 studies in Digestive System Neoplasms with a site in China, this one is the 36th largest by planned enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2015, is one of 18 in phase 1, and was the 9th registered.

Digestive System Neoplasms

195 studies on the registry are indexed under Digestive System Neoplasms; 57 are open to participants now.

Browse Digestive System Neoplasms studies →

Open to participants now

35 of the 75 studies in Digestive System Neoplasms with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Digestive System Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials. The clinical trial is divided into two parts, including single and successive administration.

Read the detailed description

To evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials. A single-arm, non-randomized, open, drug tolerance trial will be conducted. The clinical trial is divided into two parts, including single and successive administration.The single administration includes 7 groups, dose is escalated from 15ml to 180ml, with 2-6 patients per dose level. Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. This treatment will be given only once, and the volunteers will be observed for 24 hours. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc. The successive administration includes 2 groups, according to the result of single administration, choose the second largest tolerance dose to conduct the 1st group of successive administration. If there are significant adverse effects, then drop to a lower dose to conduct the 2nd group; if the trial shows no adverse effects, it upgrades to a higher dose (the maximum tolerated dose) to conduct the 2nd group. The treatment will be given 3 times a week, 2 weeks as a period. Adverse effects will be evaluated during and after treatment.

03

Conditions studied

  • Digestive System Cancer
  • Malignant Ascites
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. digestive system cancer with malignant ascites;
  2. the age of 18-80 years;
  3. neither systemic chemotherapy, nor peritoneal perfusion therapy in 2 weeks;
  4. no cinobufotalin preparations in 2 weeks;
  5. score 0-3;
  6. the amount of ascites is above level II (1000-3000ml);
  7. volunteer to participate and sign .

Exclusion criteria

Exclusion Criteria:

  1. non-cancer causes of ascites, such as peritonitis, cirrhosis,hypoalbuminemia;
  2. Had an allergy history to toad's skin or its products or had adverse reactions like arrhythmia when applied before;
  3. B ultrasound or CT confirmed the peritoneal cavity is separated which will affect the treatment of ascites and the estimation of ascites;
  4. The conditions admit and the patients would better to undergo chemotherapy of malignant ascites;
  5. cardiac function is Ⅲ-Ⅳ;
  6. > 3 times upper limit and / or > 2 times upper limit;
  7. renal function is phase 3 and above 3;
  8. have severe neutropenia of degree II or above, and / or moderate or severe anemia, and / or thrombocytopenia of degree II or above;
  9. Consolidated mental disorders.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    cinobufacini group

    48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.

    Drug: Cinobufacini Injection

Interventions

  • DrugHuachansuStudies of HuachansuHuachansu pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.

06

What researchers measure

Primary outcomes

  1. the grade of adverse events

    According to The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 4.0),grade the severity of adverse events (AE) that occur with drug treatment,which include symptoms, electrocardiogram, blood routine, urine routine, hepatic and renal function. Each item is graded 1-5.

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
  • Oncology dept; Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
    Beijing, Beijing 100078, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Apr 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2015
First posted
Aug 21, 2015
Start
Jul 2015
Primary completionEst.
Apr 2018
CompletionEst.
Jun 2018
Last update
Aug 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02530398
Lead sponsor
Dongfang Hospital Beijing University of Chinese Medicine
Responsible party
Quanwang Li (Chief of oncology dept, Dongfang Hospital Beijing University of Chinese Medicine) — Principal investigator
First posted
Aug 21, 2015
Start date
Jul 2015
Primary completion
Apr 2018 (estimated)
Completion
Jun 2018 (estimated)
Last update
Aug 30, 2017

Study contacts

Quanwang Li, master
Contact
quanwangli@126.com
86-010-67689787

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huachansu

Start the discussion